Back to library

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Melanocortin Agonist · Sexual Health

Bremelanotide (Vyleesi)

Melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women.

FDA-Approved

Plain-Language Label Highlights

Brand names: Vyleesi

What it's approved for

Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

An on-demand injection that activates brain pathways tied to sexual desire. Used as needed before intimacy, not daily.

Common side effects
  • Nausea
  • Flushing
  • Headache
  • Vomiting
  • Cough
Serious risks to know
  • Transient increases in blood pressure
  • Focal hyperpigmentation (skin darkening)
Who should avoid or use with extra caution
  • Uncontrolled hypertension
  • Known cardiovascular disease
  • Pregnancy

Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.

Mechanism of Action

Cyclic 7-amino-acid synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the CNS, modulating sexual desire pathways.

Research Areas

Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women

Common Research Protocols

On-demand

1.75 mg SC at least 45 minutes before anticipated sexual activity (max 1 dose/24h, 8/month).

Protocols summarized for educational reference from published research. Not dosing guidance.

Cited Research

[1]Obstetrics & Gynecology·2019

RECONNECT trials

Improved desire and reduced distress vs placebo in premenopausal HSDD.

Important Considerations

  • FDA-approved.
  • Nausea, flushing, transient BP elevation common.

Explore more peptides

Educational Information Only — Not Medical Advice

All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.

Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.

Searching the library…

Ask the Library

Ask anything about peptides — answers come from our curated reference library with citations.

Find a pharmacy that carries Bremelanotide (Vyleesi)

Leave your details and a vetted partner pharmacy will reach out with availability and pricing.